EMMPRIN (CD147) Ein prognostischer und potenzieller therapeutischer Marker im Urothelkarzinom

Translated title of the contribution: EMMPRIN (CD147). a prognostic and potentially therapeutic marker in urothelial cancer

R. Nawroth, A. Hartmann, P. Wild, J. Lehmann, R. Stöhr, J. E. Gschwend, M. Retz

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


In 50% of all cases, bladder cancer patients develop tumor progression despite modern surgical methods such as radical cystectomy. A solution to the problem might be the identification and understanding of molecular biomarkers which could result in the development of advanced methods with better preventive, diagnostic, and therapeutic potential. One suitable approach is the identification of a bladder cancer-specific molecular marker in order to enhance patients' outcome. We and others have identified EMMPRIN as a prognostic biomarker in a variety of tumor diseases. EMMPRIN (CD147, extracellular matrix metalloproteinase inducer) is a cell surface protein that is expressed among other cell types, in particular in tumor cells. Since its first description in 1982 it is established that overexpression of EMMPRIN correlates with tumor progression and patient outcome. EMMPRIN expression levels can be used as an independent prognostic factor for survival. Recently, EMMPRIN has been defined as a potential target for tumor therapy in preclinical studies.

Translated title of the contributionEMMPRIN (CD147). a prognostic and potentially therapeutic marker in urothelial cancer
Original languageGerman
Pages (from-to)251-254
Number of pages4
Issue numberSUPPL. 2
StatePublished - Oct 2010
Externally publishedYes


Dive into the research topics of 'EMMPRIN (CD147). a prognostic and potentially therapeutic marker in urothelial cancer'. Together they form a unique fingerprint.

Cite this